Skip to contentSkip to filters

We use cookies for analytics.

Part the Cloud: Phase 1 and Phase 2 Clinical Studies — 2027 Funding

Clinical Neurology, Neuropharmacology, Clinical Pharmacology and research grant from Alzheimer’s Association

Apply by Tuesday, Oct 20

Closes in 6 days

Closing time not stated; check the source.

Up to $1,000,000
Apply on funder site (opens in a new tab)

About

Supports translational studies of potential Alzheimer’s and related-dementia therapies, including early human safety, target engagement and proof of mechanism. Awards provide up to USD 1 million over two to three years; selected Phase 3 or biomarker-validation proposals can also qualify. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

Eligibility

Career stage: Early independent researcher · Mid-career researcher · Established researcher

Institution applies

Covers: Up to USD 1 million total over two to three years.

Host location: Worldwide

International applicants, including eligible institutions in Austria and Europe; organisation and sanctions exclusions apply.

Eligibility sourceSource 2

Reviewed Sep 24, 2026. Check the funder’s full conditions before applying.

Full-time investigators at Assistant Professor level or equivalent and above; students and postdocs cannot be lead applicants. Eligible international institutions may apply, subject to programme and sanctions rules. Only one proposal per applicant across the current competition; reporting and institutional exclusions apply.

Topics

Alzheimer’stranslational studieshuman safetytarget engagementproof of mechanismPhase 3ISTAART

Related funding

Open funding in Clinical Neurology

All funding

Open jobs in Clinical Neurology

All jobs

Source: alz.org